Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Gain on sale of PREBOOST® business

Impairment of intangible assets

Provision for (recovery of) credit losses

Gain on sale of ENTADFI® assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veru reports positive Phase III results for sabizabulin in COVID-19

Veru's positive Phase III trial results for sabizabulin in COVID-19 highlight its potential in reducing mortality.
Financially, challenges persist with decreased revenues and increased expenses, but the company is focused on growth strategies.
The company's strengths lie in sabizabulin's unique mechanism, clinical trial prioritization, and revenue generation plans.
Opportunities for Veru include commercializing sabizabulin, driving revenue growth, and advancing oncology trials.

Veru reports Q2 financial challenges but shows promise in clinical developments

Veru Inc. faced financial challenges in Q2 2023 with decreased net revenues and significant operating losses, prompting efforts to manage costs and explore strategic options.
Despite the financial hurdles, the company demonstrated strengths in clinical developments, securing additional funding, and pursuing growth opportunities in breast cancer and viral ARDS treatments.
Veru's focus on increasing revenues through marketing efforts, expanding distribution channels, and seeking strategic partnerships positions the company for future growth and success in the pharmaceutical industry.

Veru reports mixed Q3 results, eyes partnerships and market expansion

Veru Inc. faced challenges with a decrease in net revenues but achieved a net income for Q3 2023.
Strengths lie in promising results of enobosarm and sabizabulin studies, FDA clarity, and improved cash position.
Opportunities include expanding evaluation of sabizabulin, seeking partnerships, and market expansion through tenders.
The company needs to address challenges of net losses, high operating expenses, and maintaining adequate cash reserves.

Veru Inc. reports Q4 earnings, pursues partnerships for drug development

Veru Inc. reported a decrease in net revenues but secured significant funding through a successful public offering. Their drug development program, particularly enobosarm and sabizabulin, holds promise for multiple medical applications. The pursuit of partnerships and the potential for combination treatments present opportunities for future growth.

Veru Inc. reports Q1 growth, seeks partners for enobosarm study

Veru Inc. demonstrates financial progress and strategic initiatives in drug development, positioning itself for future growth and innovation.
The company's focus on enobosarm's potential in weight loss and oncology, along with seeking partnerships, reflects a proactive approach to advancing its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

MIAMI, March 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that the Company will present at the Oppenheimer 32nd Annual Healthcare Conference. The presentation will be available through the Conference on March 15, 2022, at 11:20 am Eastern Time.

Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022

MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent will be presented at the 2022 ASCO Genitourinary Cancers Symposium being held February 17-19, 2022 in San Francisco, CA. Sabizabulin is an oral new chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt the cytoskeleton.

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium

--Planned Conditional Statistical Power Analysis was Conducted—

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call Transcript

--FC2 Prescription Business Entering 6 th Year of Growth -- --FDA Approves Company's ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway--

Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%

The consensus price target hints at a 343.6% upside potential for Veru Inc. (VERU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Veru Inc. (VERU) Climb 344% to Reach the Level Wall Street Analysts Expect?

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Veru Inc. (VERU) Q1 Earnings Expected to Decline

-- Phase 3 ENABLAR-2 Clinical Trial for 2 nd  Line Treatment of AR+ER+HER2- Metastatic Breast Cancer Expected to Commence During First Quarter of 2022 -- MIAMI, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of enobosarm, Veru's oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor (AR), a tumor suppressor, in combination with Lilly's Verzenio® (abemaciclib), a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer.

Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial

The FDA has granted Fast Track designation to Veru Inc's VERU sabizabulin, oral cytoskeleton disruptor, to combat COVID-19 infection and the cytokine storm responsible for Acute Respiratory Distress Syndrome (ARDS) and death.  [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Veru's Cancer Candidate Sabizabulin Gets FDA Fast Track Tag For COVID-19

-- Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico, South America, and Europe; Clinical Results Expected 1H 2022 -- -- Second Veru Drug Under Development to Receive FDA Fast Track Designation this Month --

Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2022 first quarter, on Wednesday, February 9, 2022, before the market opens. Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.

Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th

The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug

The company wins Fast Track designation for a top pipeline program.

Why Veru Stock Triumphed on Tuesday

MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will present at the H.C. Wainwright BioConnect Conference. The presentation will be available through the Conference from January 10-13, 2022, beginning at 7:00 am Eastern Standard Time on January 10th.

Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022

-- ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia-- --Commercialization Will Start Early Calendar Year 2022--

Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer, today announced that human preclinical data will be presented demonstrating that enobosarm treatment alone as well as in combination with a CDK4/6 inhibitor increased androgen receptor (AR) expression resulting in the synergistic suppression of breast cancer cell and tumor models that are resistant to CDK4/6 inhibitors and estrogen blocking agents. Enobosarm is an oral, first-in-class, selective androgen receptor targeted agonist for the androgen receptor, a tumor suppressor, being evaluated in Phase 3 clinical studies to treat AR+ER+HER2- metastatic breast cancer without unwanted masculinizing side effects. The presentation was selected as a spotlight presentation at the San Antonio Breast Cancer Symposium being held December 07-10, 2021, in San Antonio, TX.

Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Sy

Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2021 Results - Earnings Call Transcript

Veru Inc. (VERU) delivered earnings and revenue surprises of 37.50% and 14.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q4 Loss, Misses Revenue Estimates

Veru (NASDAQ:VERU) reported its Q4 earnings results on Thursday, December 2, 2021 at 06:30 AM. Here's what investors need to know about the announcement.

Veru: Q4 Earnings Insights

--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico, South America, and Europe; Clinical Results Expected 1H 2022--

Veru Reports Record Fiscal 2021 Full-Year Financial Results

Veru (NASDAQ:VERU) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement.

Earnings Outlook For Veru

Analysts Estimate Veru Inc. (VERU) to Report a Decline in Earnings: What to Look Out for

Veru Inc. is a rare thing in biotech - a profitable business carrying out 3 pivotal trials for drugs in development targeting oncology and COVID.

Veru Inc.: Women's Health, COVID Trial, Oncology Pipeline - 3 Opportunities For The Price Of 1

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2021 fourth quarter and full year ended September 30, 2021, on Thursday, December 2, 2021, before the market opens. Veru's management will host a conference call that same day at 8 a.m. ET to review the Company's performance and to answer questions. The call will also be accessible via webcast.

Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd

-- Veru is a Late-Stage Clinical Development Biopharmaceutical Company Developing Drugs for the Treatment of Breast Cancer, Prostate Cancer, and COVID-19, Large Premium Global Markets–

News for Veru Stock (VERU)